Sodium valproate trenbolone enanthate gains content increases GABA (gamma-aminobutyric acid) in the brain, which correspondingly increases the content of GABA in the postsynaptic neurons. Moreover, sodium valproate affects the transfer of potassium ions across neuronal membranes. The result of this action is the inhibition of the WHO the emergence and spread of epileptic excitation for neurons.Valproate has anticonvulsant activity in various types of epilepsy in humans. The drug does not have a pronounced hypnotic and sedative effects, and are not depressing the respiratory center. Trenbolone enanthate gains no adverse effect on blood pressure, heart rate, renal function and body temperature.
bioavailability of the drug – about 100%. Peak plasma concentrations are attained within 2-8 hours after oral application of tablets with controlled release. 80-90% of the drug binds to plasma proteins, half-life is approximately 8-20 hours (in children is shorter). Therapeutic effectiveness is manifested in concentration of valproic acid in blood plasma of 40-100 mg / l. At the same time, the pharmacological and therapeutic effects of the drug controlled release does not always depend on its concentration in plasma. The volume of distribution – 0.2 liters / kg of body weight. The drug is metabolized in the liver and excreted in the urine. For a given product is not marked first-pass metabolism.
Treatment or generalized partial epilepsy, especially when these types of seizures:
- simple or combined seizures
- secondary generalized seizures
specific syndromes (West, Lennox-Gastaut syndrome)Dosing and AdministrationThe dosage regimen is selected individually depending on the age and weight of the patient.
Adults: initial dose – 600 mg / day. Increasing the dose to 200 mg every three days until the optimum effect.
The tablets should be swallowed whole with a little water. Take 1-2 times a day. The maximum recommended dose of 1-2
children weighing more than 20 kg: initial dose – 400 mg / day. Gradually increase the dosage until the optimal, typically 20-30 mg / kg once a day or two divided doses.
Children weighing 20 kg should not be applied to children XP valparin this category.
Elderly patients: The dosage regimen is similar to XP valparin dosing schedule for adults and adjusted individually.Contraindications
Individual intolerance of the drug expressed by the human pancreas, acute or chronic hepatitis, active hepatitis B cases in the family history, especially of medicinal origin, pregnancy, lactation, porphyria, anemia, children up to 3 years.
In rare cases, the reported occurrence of the following side effects: nausea, vomiting, diarrhea and / or constipation; hepatitis; pancreatitis; weight gain, skin rash, itching, photosensitivity, erythema multiforme, Stevens-Johnson syndrome; hair loss (in 2-12% of patients); ataxia, tremor, impaired consciousness, coma; menstrual irregularities, secondary amenorrhea; anemia, giperkreatinemiya, thrombocytopenia, neutropenia, leukopenia, decreased fibrinogen, platelet aggregation inhibition.
Use caution when operating machinery, because drug weakens attention. It should be regular monitoring of transaminase levels, bilirubin, blood platelets, amylase (every 3 months).
Valproic acid inhibits platelet aggregation, which increases the risk of increased blood clotting bleeding. It is necessary to consider the possibility of complications related to bleeding in the operated patients receiving valproate XP. Patients taking the drug for a long time, may develop spontaneous bruising and bleeding. In this case, you should immediately stop taking the drug.
Valproate can cause drug pancreatitis and liver dysfunction (usually in the first 6 months of use). In connection with this is necessary during the first 6 months of treatment to monitor the status of the pancreas, liver function tests to conduct, to monitor the levels of prothrombin. Violation of the liver, liver failure during treatment with valproate is sometimes observed in children with epilepsy and combined metabolic and degenerative disorders, organic disorders of the brain tissue, and delayed mental development. If you have symptoms such as severe weakness, lethargy, swelling, vomiting, jaundice, you should immediately stop using the product.
Pregnancy and lactation
Appointment of the drug for pregnant women is possible only when the intended benefits to the mother outweighs the potential risk to the fetus. In the case of receiving the drug during pregnancy is required to conduct specialized prenatal monitoring of the fruit.
Use of the drug during breast feeding is not recommended.
Interaction with other drugs
Valproate increases the effects of antipsychotics, anticonvulsants and antidepressants. Unlike other anticonvulsants valproate causes no induction of liver enzymes, however does not reduce the effectiveness of oral contraceptives. In a joint application and valproate warfarin reduced the percentage of binding to plasma proteins of the latter. Valproate alter plasma concentrations of phenytoin and lamotrigine. In combination with anticoagulants and derivatives of acetylsalicylic acid increases the inhibition of platelet aggregation.
It was reported about rare cases of accidental or intentional overdose. At the same time there was a nausea, vomiting, dizziness, diarrhea, respiratory depression, hyporeflexia, coma. First Aid: gastric lavage, activated charcoal. If necessary – patient treatment with symptomatic therapy, hemodialysis.
10 tablets in a strip of aluminum foil. 3 strip or strips 10 with instructions for use are packed in a cardboard box
Sample not for sale: 4 or 10 tablets in a strip of aluminum foil; 1 strip with instructions for use is packed in a cardboard box.